All Stories

  1. Advances in genetics: widening our understanding of prostate cancer

    Article • F1000Research, June 2016, Faculty of 1000, Ltd.

    Dr Greg N Brooke

  2. Antiandrogens Act as Selective Androgen Receptor Modulators at the Proteome Level in Prostate Cancer Cells

    Article • Molecular & Cellular Proteomics, February 2015, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Greg N Brooke

  3. The co-chaperone p23 promotes prostate cancer motility and metastasis

    Article • Molecular Oncology, September 2014, Wiley

    Dr Greg N Brooke

  4. Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

    Article • Breast Cancer Research and Treatment, August 2014, Springer Science + Business Media

    Dr Greg N Brooke

  5. Revising the role of the androgen receptor in breast cancer

    Article • April 2014, Bioscientifica

    Dr Greg N Brooke

  6. Circulating nucleic acids as biomarkers of prostate cancer

    Article • Biomarkers in Medicine, December 2013, Future Medicine

    Dr Greg N Brooke

  7. Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells

    Article • August 2013, Bioscientifica

    Dr Greg N Brooke, Dr Simak Ali

  8. Role of the HSP90-Associated Cochaperone p23 in Enhancing Activity of the Androgen Receptor and Significance for Prostate Cancer

    Article • Molecular Endocrinology, October 2012, Endocrine Society

    Dr Greg N Brooke

  9. Allosteric Conversation in the Androgen Receptor Ligand-Binding Domain Surfaces

    Article • Molecular Endocrinology, July 2012, Endocrine Society

    Dr Greg N Brooke

  10. Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens

    Article • Oncogene, December 2011, Springer Science + Business Media

    Dr Greg N Brooke

  11. FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth

    Article • Cancer Research, December 2010, American Association for Cancer Research (AACR)

    Dr Greg N Brooke

  12. The Role of Androgen Receptor Mutations in Prostate Cancer Progression

    Article • Current Genomics, March 2009, Bentham Science Publishers

    Dr Greg N Brooke

  13. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression

    Article • Oncogene, November 2007, Springer Science + Business Media

    Dr Greg N Brooke

  14. Mechanisms of androgen receptor repression in prostate cancer

    Article • Biochemical Society Transactions, December 2006, Portland Press Ltd.

    Dr Greg N Brooke

  15. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity

    Article • Oncogene, September 2006, Springer Science + Business Media

    Dr Greg N Brooke

  16. Gliotoxin Is a Dual Inhibitor of Farnesyltransferase and Geranylgeranyltransferase I with Antitumor Activity Against Breast Cancer In Vivo

    Article • Medical Oncology, January 2004, Springer Science + Business Media

    Dr Greg N Brooke

  17. Pyrazino[1,2-a]indole-1,4-diones, simple analogues of gliotoxin, as selective inhibitors of geranylgeranyltransferase I

    Article • Bioorganic & Medicinal Chemistry Letters, November 2003, Elsevier

    Dr Greg N Brooke

  18. Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase

    Article • Bioorganic & Medicinal Chemistry Letters, January 2002, Elsevier

    Dr Greg N Brooke